Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, announced on Monday the presentation of complete Phase I/II clinical data for MHB018A, a novel subcutaneous anti-IGF-1R antibody, in patients with active and chronic thyroid eye disease (TED).

The data featured in an oral presentation at ENDO 2026, the Endocrine Society's Annual Meeting held in Chicago.

According to Minghui, at the recommended Phase III dose of 450 mg once every four weeks (Q4W), MHB018A delivered robust and highly compelling clinical activity across both active and chronic TED populations. Results showed an 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chronic TED.

The drug was generally well tolerated in the Phase I/II study. Most adverse events were mild and consistent with the known mechanism of IGF-1R inhibition. All hearing-related adverse events were Grade 1 in severity, and no severe or permanent hearing damage was reported.

MHB018A is being evaluated in ongoing Phase III trials in China, with topline results anticipated in Q3 2026. Global Phase III trials have also been initiated, with first patient enrolment targeted for Q4 2026.